mTOR inhibitor

Everolimus - Temsirolimus - Temsirolimus      

pathologytreatmentpatient Demonstrated benefit and harm k      
advanced breast cancer (metastatic)everolimusnot classified

versus CT

everolimus + trastuzumab + vinorelbine superior to trastuzumab + vinorelbine alone in terms of PFS in BOLERO-3, 2014

1 trialmeta-analysis
advanced breast cancer (metastatic)everolimusnot classified

versus endocrine therapy alone

everolimus + exemestane superior to exemestane alone in terms of PFS in BOLERO-2, 2011

2 trialsmeta-analysis
advanced breast cancer (metastatic)temsirolimus not classified

versus endocrine therapy alone

No demonstrated result for efficacy

1 trialmeta-analysis
renal-cell carcinoma (advanced)everolimusnot classified

versus

No demonstrated result for efficacy

everolimus inferior to sunitinib in terms of PFS in RECORD 3, 2014

2 trialsmeta-analysis
renal-cell carcinoma (advanced)temsirolimus not classified

versus

No demonstrated result for efficacy

temsirolimus inferior to sorafenib in terms of OS in INTORSECT, 2014

2 trialsmeta-analysis